Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 15, 2019
Pharmacy Choice - Pharmaceutical News - New initiative aims to improve chances of medicines receiving positive HTA decisions [Sport360] - February 15, 2019

Pharmacy News Article

 11/23/17 - New initiative aims to improve chances of medicines receiving positive HTA decisions [Sport360]

A unique initiative launched today by muscular dystrophy charity Duchenne UK is set to radically simplify the way necessary evidence is generated for submissions made to health technology appraisals (HTA) bodies such as the National Institute for Health and Care Excellence (NICE) and the Haute Autorit de Sant (HAS).

Launched today at the 8th World Orphan Drug Congress in Barcelona, this innovative collaboration entitled HERCULES will focus on medicines used to treat Duchenne muscular dystrophy (DMD). It will be the first time a group of pharmaceutical industry partners have ever collaborated to generate, share and align disease level data across an entire condition.

Although this new initiative focuses on DMD, it paves the way for similar approaches in other rare diseases, and has the potential to improve the chances of medicines in rare and orphan diseases receiving positive HTA decisions. This unique collaborative approach has been welcomed by a range of industry health economists, as well as former NICE personnel.

Launching HERCULES at the conference, Emily Crossley, Co-Chair of Duchenne UK, commented:

Larger pharma companies can often commit considerable internal resources to the health technology appraisal process, creating bespoke economic models and quality of life measures for example. This is not always the case for smaller companies, which risks their submissions being more uncertain and patients losing out. HERCULES aims to pool resources in advance for the benefit of every company involved, drastically reducing the time spent reinventing the wheel on evidence for similar appraisals down the line. This has the potential to completely transform the way we look at HTA submissions to bodies like NICE, initially in DMD. But it could be equally transformative if adopted in other rare and orphan diseases.

Rare conditions affect around 3.5 million people in the UK, yet only 5 per cent of rare diseases have a licensed treatment option in the UK. A key issue in developing treatments for rare diseases is the limited evidence base available due to known issues, such as small patient populations for each disease. These obstacles tend to hinder the HTA approval of life-changing treatments and their subsequent availability to NHS patients, even for medicines that have received regulatory approval.

Fleur Chandler, a health economist in the pharmaceutical industry, who leads the steering group for the HERCULES initiative and is the mother of a child (Dominic) with Duchenne muscular dystrophy, added:

With HERCULES, we have a unique opportunity to develop the evidence for DMD collaboratively, reducing duplication and ultimately helping to get new treatments for DMD to the boys who need them most. Its also a great example of a patient organization taking the lead in solving a problem that the industry has talked about for a long time, but where limited progress has been made to date. Were absolutely delighted to be working with Duchenne UK to make this happen, as it has the potential to make an enormous difference to the way treatments for rare diseases are assessed.

Josie Godfrey, Director at JG Zebra Consulting Ltd and formerly Associate Director for Highly specialized Technologies and Topic Selection at NICE said:

This project is a great opportunity to create the most robust evidence base for appraising new treatments for DMD. Were doing this as part of our mission to help bring hope to families affected by DMD, and look forward to the future where our HERCULES data package can provide efficient and streamlined access to innovations in this devastating disease.



(c) 2017 Gulf Sports Media All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Feb 18: Management of Schizophrenia & Acute Agitation
Feb 19: Treatment of Atopic Dermatitis (Eczema) & Xerosis (Dry Skin)
Feb 20: Know Your Value, Know Your Worth: Provider Status in Pharmacy
Feb 21: Type II Diabetes: Case Studies and Management Options
Feb 22: Medical Marijuana: The Basic and Clinical Pharmacology, Not The Politics
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415